Cold Agglutinin Disease (CAD) poses unpredictable risk1-4
For patients with CAD, the effects of chronic hemolysis can cause acute consequences and chronic risks
CAD is a rare type of autoimmune hemolytic anemia with acute consequences and chronic risks.1-3 Hemolysis in CAD is driven by C1 activation of the classical complement pathway, when cold agglutinins (IgM autoantibodies) recruit and activate C1, typically at body temperatures under 98.6 °F (37 °C).5,6 Get a deeper look at the mechanism of hemolysis in CAD and how ENJAYMO works.

Unmet needs remain for patients despite management strategies with cold avoidance and therapies not indicated for CAD
- *The most common reasons for treatment initiation were progressive anemia (53%), treatment of other CAD symptoms (25%), and treatment of underlying disorder (12%). Underlying disorders in this analysis included MGUS, macroglobulinemia, unspecified lymphoproliferative disorder, other lymphoma (including low-grade B-cell and diffuse large B-cell lymphomas), chronic lymphocytic leukemia, and cutaneous T-cell lymphoma.
- †Study patients with CAD were initiated on therapies including corticosteroids, IV immunoglobulin, rituximab, immunosuppressants, antineoplastics (eg, bendamustine), or biologics (eg, eculizumab).
Chronic complement-mediated hemolysis in CAD drives year-round anemia, regardless of season7
In a retrospective analysis of patients with CAD (n=594)
Mean values of hemoglobin and bilirubin levels by season

below the lower limit of normal
through all 4 seasons

above the upper limit of normal
through all 4 seasons
The estimated median value for LDH was above normal for all 4 seasons
- ‡Normal hemoglobin levels for adults vary, but in general are 14 to 17 g/dL for males and 12 to 16 g/dL for females. Normal bilirubin is 0.3 to 1.2 mg/dL.